DK1703896T3 - Farmaceutiske kompositioner omfattende midazolam i en höj koncentration - Google Patents
Farmaceutiske kompositioner omfattende midazolam i en höj koncentrationInfo
- Publication number
- DK1703896T3 DK1703896T3 DK05701515T DK05701515T DK1703896T3 DK 1703896 T3 DK1703896 T3 DK 1703896T3 DK 05701515 T DK05701515 T DK 05701515T DK 05701515 T DK05701515 T DK 05701515T DK 1703896 T3 DK1703896 T3 DK 1703896T3
- Authority
- DK
- Denmark
- Prior art keywords
- midazolam
- pharmaceutical compositions
- high concentration
- compositions
- benzodiazapine
- Prior art date
Links
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003793 midazolam Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010039897 Sedation Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 238000012977 invasive surgical procedure Methods 0.000 abstract 1
- 230000036280 sedation Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000007627 surgical diagnostic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0400804.1A GB0400804D0 (en) | 2004-01-14 | 2004-01-14 | Pharmaceutical compositions |
| PCT/EP2005/050133 WO2005067893A2 (en) | 2004-01-14 | 2005-01-13 | Pharmaceutical compositions comprising midazolam in a high concentration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1703896T3 true DK1703896T3 (da) | 2009-03-02 |
Family
ID=31726180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05701515T DK1703896T3 (da) | 2004-01-14 | 2005-01-13 | Farmaceutiske kompositioner omfattende midazolam i en höj koncentration |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7700588B2 (da) |
| EP (1) | EP1703896B1 (da) |
| JP (1) | JP5085138B2 (da) |
| KR (1) | KR20060130175A (da) |
| CN (1) | CN1929816B (da) |
| AT (1) | ATE417600T1 (da) |
| AU (1) | AU2005205072B2 (da) |
| BR (1) | BRPI0506868A (da) |
| CA (1) | CA2553890C (da) |
| DE (1) | DE602005011753D1 (da) |
| DK (1) | DK1703896T3 (da) |
| EA (1) | EA014096B1 (da) |
| ES (1) | ES2319667T3 (da) |
| FI (2) | FIC20230023I1 (da) |
| GB (1) | GB0400804D0 (da) |
| IL (1) | IL176774A0 (da) |
| MX (1) | MXPA06008086A (da) |
| NO (3) | NO336916B1 (da) |
| NZ (1) | NZ548454A (da) |
| PL (1) | PL1703896T3 (da) |
| PT (1) | PT1703896E (da) |
| WO (1) | WO2005067893A2 (da) |
| ZA (1) | ZA200606310B (da) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040176359A1 (en) * | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
| KR101434522B1 (ko) * | 2005-11-09 | 2014-08-26 | 오닉스 세라퓨틱스, 인크. | 효소 저해를 위한 화합물 |
| US7691852B2 (en) | 2006-06-19 | 2010-04-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
| WO2008089426A2 (en) * | 2007-01-19 | 2008-07-24 | Hananja Ehf | Methods and compositions for the delivery of a therapeutic agent |
| US20080275030A1 (en) | 2007-01-19 | 2008-11-06 | Sveinbjorn Gizurarson | Methods and Compositions for the Delivery of a Therapeutic Agent |
| EP2194965B1 (en) | 2007-08-31 | 2016-07-20 | Archimedes Development Limited | Non-aqueous pharmaceutical compositions |
| US8507468B2 (en) * | 2007-10-02 | 2013-08-13 | Robert Orr | Intranasal anti-convulsive compositions and methods |
| RS54847B2 (sr) | 2007-10-04 | 2019-09-30 | Onyx Therapeutics Inc | Inhibitori kristalne peptid epoksi keton proteaze i sinteza aminokiselinskih keto-epoksida |
| CA2756690C (en) | 2008-03-28 | 2016-08-16 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
| JP5675629B2 (ja) | 2008-10-21 | 2015-02-25 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ペプチドエポキシケトンを用いた併用療法 |
| AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
| JP5919196B2 (ja) | 2009-11-13 | 2016-05-18 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 転移抑制のためのペプチドエポキシケトンの使用 |
| MA34133B1 (fr) | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
| WO2011136905A2 (en) | 2010-04-07 | 2011-11-03 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
| GB2481407B (en) * | 2010-06-22 | 2012-05-23 | Special Products Ltd | A rapid onset liquid midazolam composition for buccal administration |
| CN102309438B (zh) * | 2010-07-02 | 2013-04-17 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种咪达唑仑药物组合物及其用途 |
| CN102335430B (zh) * | 2010-07-14 | 2013-07-31 | 中国人民解放军军事医学科学院毒物药物研究所 | 包含咪达唑仑与神经保护剂的复方药物组合物 |
| CN102462685B (zh) * | 2010-11-10 | 2014-07-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种咪达唑仑组合物、其制备方法及用途 |
| SG194927A1 (en) | 2011-05-13 | 2013-12-30 | Euro Celtique Sa | Intranasal pharmaceutical dosage forms comprising naloxone |
| PL3415139T3 (pl) | 2011-06-14 | 2022-07-11 | Neurelis, Inc. | Podawanie benzodiazepiny |
| US20140105921A1 (en) | 2012-07-09 | 2014-04-17 | Onyx Therapeutics, Inc. | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors |
| US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| US20200297734A1 (en) * | 2015-06-19 | 2020-09-24 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
| WO2017218344A1 (en) | 2016-06-14 | 2017-12-21 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods for treating neurological conditions and exposure to nerve agents |
| WO2019226753A1 (en) | 2018-05-25 | 2019-11-28 | Ucb Biopharma Sprl | Benzodiazepine formulations |
| WO2020129085A1 (en) | 2018-12-18 | 2020-06-25 | Cipla Limited | Intranasal formulation |
| US20210322343A1 (en) * | 2020-04-15 | 2021-10-21 | Farzana Shaheen | Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders |
| CN113209013B (zh) * | 2021-06-24 | 2023-04-07 | 新疆特丰药业股份有限公司 | 一种咪达唑仑液体制剂及其制备方法和用途 |
| NL2031331B1 (en) | 2022-03-18 | 2023-09-29 | Plethora Therapeutics B V | Transmucosal delivery of a short-acting psychedelic compound |
| NL2031332B1 (en) | 2022-03-18 | 2023-09-29 | Plethora Therapeutics B V | Transmucosal delivery of psychoactive compounds |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3812853A (en) | 1971-11-17 | 1974-05-28 | P Crain | Apparatus for applying medication or the like to human nasal passages |
| US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US5132114A (en) | 1985-05-01 | 1992-07-21 | University Of Utah Research Foundation | Compositions and methods of manufacture of compressed powder medicaments |
| US4889860A (en) | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
| EP0259383B1 (de) | 1986-03-10 | 1991-01-23 | Kurt Dr. Burghart | Pharmazeutikum sowie verfahren zu seiner herstellung |
| US4673679A (en) | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
| US4782047A (en) | 1986-05-22 | 1988-11-01 | Syntex Pharmaceuticals International Ltd. | Aqueous steroid formulations for nasal administration |
| DE3734306A1 (de) | 1987-10-10 | 1989-04-27 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung fuer fliessfaehige medien |
| US4973596A (en) | 1988-05-20 | 1990-11-27 | Barr Laboratories, Inc. | Method of administering a narcotic analgesic and dosage forms therefor |
| US4950664A (en) | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
| US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5766573A (en) | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| JP3219096B2 (ja) * | 1990-05-10 | 2001-10-15 | ニコメド ファーマ エイエス | ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤 |
| US5397771A (en) * | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
| FR2662672B1 (fr) | 1990-05-31 | 1992-08-21 | Aerosols & Bouchage | Dispensateur de melange. |
| US5166202A (en) * | 1990-09-19 | 1992-11-24 | Trustees Of The University Of Pennsylvania | Method for the treatment of panic disorder |
| HUT67449A (en) | 1991-06-10 | 1995-04-28 | Schering Corp | Aerosol formulations containing 1,1,1,2,3,3,3-heptafluoropropane |
| GB9125699D0 (en) | 1991-12-03 | 1992-01-29 | Glaxo Group Ltd | Device |
| GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| RO113214B1 (ro) | 1992-10-19 | 1998-05-29 | Dura Pharma Inc | Inhalator de pulbere uscata |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| US6228383B1 (en) | 1994-03-03 | 2001-05-08 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
| GB9409778D0 (en) | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
| CA2152684A1 (en) | 1994-07-01 | 1996-01-02 | Richard Anthony Henry | Aerosol delivery of midazolam |
| US5529787A (en) | 1994-07-07 | 1996-06-25 | Alza Corporation | Hydromorphone therapy |
| DE19536244A1 (de) | 1994-09-30 | 1996-04-04 | Juergen Dr Regenold | Pharmazeutische Zusammensetzung zur lokalen Applikation |
| US5866143A (en) | 1995-03-24 | 1999-02-02 | El Khoury And Stein, Ltd. | Topical application of opioid drugs such as morphine for relief of itching and skin disease |
| US5622166A (en) | 1995-04-24 | 1997-04-22 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
| US5637314A (en) | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
| US5948389A (en) | 1995-06-07 | 1999-09-07 | El Khoury & Stein, Ltd. | Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics |
| US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| EP1024833A1 (en) | 1996-07-11 | 2000-08-09 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
| DE19709702A1 (de) | 1997-03-10 | 1998-09-17 | Wolff Walsrode Ag | Lackbindemittelzubereitungen, deren Herstellung und Verwendung |
| US5855907A (en) | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
| FR2772271B1 (fr) | 1997-12-11 | 2000-09-01 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
| NZ505951A (en) * | 1998-02-23 | 2003-02-28 | Cyclops Ehf | A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening |
| US6699849B1 (en) | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
| DE19807921A1 (de) | 1998-02-25 | 1999-08-26 | Pfeiffer Erich Gmbh & Co Kg | Austrag-Steuerung für einen Medien-Spender |
| US6608073B1 (en) | 1998-10-14 | 2003-08-19 | New Millennium Pharmaceutical Research, Inc. | Intranasal codeine for the rapid suppression of cough and rapid relief of pain |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| AU5397300A (en) | 1999-06-02 | 2000-12-28 | Hexal Ag | Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water |
| KR100715513B1 (ko) | 1999-07-26 | 2007-05-08 | 에스케이 코오포레이션 | 경비 항경련성 조성물 |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| WO2001030391A2 (en) | 1999-10-27 | 2001-05-03 | Farmarc Nederland Bv | Pharmaceutical composition containing midazolam |
| US6610271B2 (en) | 2000-05-10 | 2003-08-26 | University Of Kentucky Research Foundation | System and method for intranasal administration of lorazepam |
| US20040176359A1 (en) | 2001-02-20 | 2004-09-09 | University Of Kentucky Research Foundation | Intranasal Benzodiazepine compositions |
| US20030027833A1 (en) | 2001-05-07 | 2003-02-06 | Cleary Gary W. | Compositions and delivery systems for administration of a local anesthetic agent |
| ES2316571T3 (es) | 2001-05-24 | 2009-04-16 | Alexza Pharmaceuticals, Inc. | Administracion de alprazolam, estazolam, midazolam o triazolam a traves de una via inhalatoria. |
| GB0116107D0 (en) | 2001-06-30 | 2001-08-22 | West Pharm Serv Drug Res Ltd | Pharmaceutical composition |
| GB0130964D0 (en) | 2001-12-24 | 2002-02-13 | Special Products Ltd | Pharmaceutical composition |
| US20060039869A1 (en) | 2004-08-17 | 2006-02-23 | Daniel Wermeling | Intranasal delivery of antipsychotic drugs |
-
2004
- 2004-01-14 GB GBGB0400804.1A patent/GB0400804D0/en not_active Ceased
-
2005
- 2005-01-13 US US11/034,474 patent/US7700588B2/en active Active
- 2005-01-13 WO PCT/EP2005/050133 patent/WO2005067893A2/en not_active Ceased
- 2005-01-13 MX MXPA06008086A patent/MXPA06008086A/es unknown
- 2005-01-13 PL PL05701515T patent/PL1703896T3/pl unknown
- 2005-01-13 DE DE602005011753T patent/DE602005011753D1/de not_active Expired - Lifetime
- 2005-01-13 EP EP05701515A patent/EP1703896B1/en not_active Expired - Lifetime
- 2005-01-13 PT PT05701515T patent/PT1703896E/pt unknown
- 2005-01-13 NZ NZ548454A patent/NZ548454A/en not_active IP Right Cessation
- 2005-01-13 AU AU2005205072A patent/AU2005205072B2/en not_active Expired
- 2005-01-13 KR KR1020067016194A patent/KR20060130175A/ko not_active Withdrawn
- 2005-01-13 ES ES05701515T patent/ES2319667T3/es not_active Expired - Lifetime
- 2005-01-13 BR BRPI0506868-1A patent/BRPI0506868A/pt not_active Application Discontinuation
- 2005-01-13 CA CA2553890A patent/CA2553890C/en not_active Expired - Lifetime
- 2005-01-13 AT AT05701515T patent/ATE417600T1/de active
- 2005-01-13 JP JP2006548318A patent/JP5085138B2/ja not_active Expired - Fee Related
- 2005-01-13 DK DK05701515T patent/DK1703896T3/da active
- 2005-01-13 CN CN2005800078503A patent/CN1929816B/zh not_active Expired - Lifetime
- 2005-01-13 EA EA200601309A patent/EA014096B1/ru not_active IP Right Cessation
- 2005-09-08 US US11/221,663 patent/US20060009447A1/en not_active Abandoned
-
2006
- 2006-07-10 IL IL176774A patent/IL176774A0/en unknown
- 2006-07-26 NO NO20063453A patent/NO336916B1/no active Protection Beyond IP Right Term
- 2006-07-31 ZA ZA200606310A patent/ZA200606310B/xx unknown
-
2023
- 2023-03-16 NO NO2023011C patent/NO2023011I1/no unknown
- 2023-03-21 NO NO2023014C patent/NO2023014I1/no unknown
- 2023-07-11 FI FIC20230023C patent/FIC20230023I1/fi unknown
- 2023-07-19 FI FIC20230024C patent/FIC20230024I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20230024I1 (fi) | Farmaseuttisia koostumuksia, jotka käsittävät midatsolaamia suuressa pitoisuudessa | |
| TW200744665A (en) | Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof | |
| UA97795C2 (uk) | Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки | |
| EA201270666A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| AR059948A1 (es) | Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa | |
| EA200970287A1 (ru) | Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты | |
| UY30477A1 (es) | Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| LU92232I2 (fr) | "Florbétapir (18 F)" | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| EP2279244A4 (en) | METHOD AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | |
| CY1116831T1 (el) | ΧΡΗΣΗ 24-norUDCA | |
| EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
| MX2008013017A (es) | Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl. | |
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
| EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
| EA200702253A1 (ru) | Фармацевтическая композиция | |
| MA32588B1 (fr) | Derives azotes de la pancratistatine | |
| EA200900269A1 (ru) | Лекарственные комбинации для лечения заболеваний дыхательных путей | |
| ECSP109871A (es) | Soluciones farmacéuticas orales que contienen telbivudina | |
| MY160005A (en) | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt | |
| MY145122A (en) | Phenylacetic acid derivatives as cox-2 inhibitors | |
| UA107716C2 (ru) | Терапевтическое средство с замедленным высвобождением на основе соединения 2-фенилтиазола для гипертонии и почечной дисфункции | |
| EA200901145A1 (ru) | Применение рибофлавина в лечении гипертензии | |
| WO2006121857A3 (en) | Unsolvated and host-guest solvated crystalline forms of (2e,4s)-4-[(n-{[(2r)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-l-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses |